On July 31, MEDBOT-B rose 5.5% in regular trading, trading at approximately 21.08 HKD/share, with turnover of 46.56 million HKD. The stock had previously pulled back approximately 5% over two consecutive sessions following its profit alert rally, with short-term profit-taking now largely absorbed.

On the news front, Dahua Capital yesterday initiated coverage on the company with a Buy rating and a target price of 29 HKD, providing support for the rebound. Fundamentally, the company achieved its first-ever half-year profit, expecting net profit of RMB 28-40 million for H1, with revenue surging 200%-230% year-over-year. Its core Toumai surgical robot saw overseas revenue growth exceeding 450%, while overall gross margin improved by more than 15 percentage points.

Within the Health Care Equipment sector, broader sentiment recovered, with MICROPORT up 2.69% and LIFETECH SCI up 3.57%, as sector-wide fund inflows supported constituent names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)